Tarcocimab tedromer was noninferior to aflibercept in change from baseline in best corrected visual acuity in patients with macular edema due to retinal vein occlusion, according to a press release from Kodiak Sciences.
In the BEACON phase 3 clinical trial, 568 participants with vision loss and macular edema due to retinal vein occlusion (RVO) were randomly assigned to receive tarcocimab tedromer (KSI-301) 5 mg every 8 weeks following two initial monthly loading doses or aflibercept 2 mg every 4 weeks. The primary efficacy endpoint was the change in BCVA from baseline to 24 weeks, which